ReviewFrontiers in oncology2025
CircRNA: the potential biomarkers and therapeutic targets in oral squamous cell carcinoma (OSCC).
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Role of circular RNAs in regulating toxicity induced by cancer therapies.Genes & diseases · 2026Review
- Novel Disease-Specific Panel of Salivary microRNAs for the Detection of Oral Squamous Cell Carcinoma from Early Invasion to Stage IV Disease.International journal of molecular sciences · 2026Article
- The mechanism of lncRNA PVT1 in oral squamous cell carcinoma.Frontiers in oncology · 2026Review
- Dissecting the role of epigenetic regulation in oral squamous cell carcinoma microenvironment: mechanisms and therapeutics.Frontiers in immunology · 2026Review
- Article
- FTO enhances OSCC progression via m⁶A-dependent stabilization of PKM2 mRNA through YTHDF2 modulation.Head & face medicine · 2025Article
- Mechanisms of circular RNAs in diabetic cardiomyopathy: biological characteristics and clinical prospects.Frontiers in genetics · 2025Review
- TNFRSF10B, a Therapeutic Target for Oral Squamous Cell Carcinoma Through Integrated Bioinformatics and Preliminary Experiments.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNAs (circRNAs) are a new category of non-coding RNAs implicated in the molecular pathology of cancer, such as oral squamous cell carcinoma (OSCC). Circular intronic RNAs (ciRNAs), exonic circRNAs (ecircRNAs), and exon-intron circRNAs (EIciRNAs) are three primary types of circRNAs resulted from the circularization of extron and intron which give rise to the distinct biology of circRNAs. Due to their unique structure and biogenesis, circRNAs exhibit tissue- and cell-specific expression profiles. Recent studies have highlighted that in OSCC, some circRNAs are differentially expressed compared with adjacent normal tissues, with these variables potentially influencing OSCC initiation and progression through diverse mechanisms. Furthermore, earlier clinical trials have indicated that circRNAs could be considered as potential therapeutic targets and biomarkers for OSCC. It should be noted that many circRNAs modulate tumor cells proliferation/apoptosis and metastasis via regulating gene transcription and post transcriptional expressions. Furthermore, certain circRNAs function as effective microRNA sponges, thereby inhibiting oncogenic pathways in OSCC. In summary, the discovery of circRNAs has unveiled new avenues for cancer research, particularly in OSCC. This review provides an overview of circRNA biogenesis, their biological functions, and their roles as differentially expressed molecules in OSCC, emphasizing their potential for clinical application and warranting further investigation into their functional and therapeutic relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.